HONEST-PREPS Enrolled Over 1700 Patients

This is a significant achievement for everyone involved in the study. It shows the dedication and commitment by the participating local sites’ teams working in ICU’s who continuously enrol patients during the difficult and challenging COVID waves.

Sites that had their study preparations delayed due to the pandemic, had a final opportunity to start-up in the HONEST-PREPS study at the end of 2021. As a result, three additional sites were activated in November 2021: one in Romania, one in Czech Republic and one in Croatia.

An interim data analysis was performed in November and December of last year. As a result of this, a report will be written on the primary endpoints. Furthermore, all participating sites were invited to participate in an EQA-panel organized by LAB-net. It will consist of 10 swabs as samples that contain HAP/VAP-related bacterial pathogens. In addition to detecting strains, the sites will also have the option to enter antimicrobial susceptibility testing results.

For the remainder of the study, all the recruiting sites will focus on reaching their inclusion targets and meeting the qualification criteria to join Ecraid’s POS-ICU-VAP study after the HONEST-PREPS study ends. The primary objective of POS-ICU-VAP is to provide an infrastructure capable of rapidly implementing randomized controlled trials and other clinical trials related to prevention, diagnosis or treatment of VAP (Ventilator-Associated Pneumonia) in ICUs. The study team aims at activating 40 ICU sites in 15 European countries and enrolling 20.000 patients in 4 years.

ABOUT HONEST-PREPS

HONEST-PREPS will determine the incidence, microbiological etiology (including antibiotic resistance), management and outcome of hospital acquired and ventilator associated pneumonia (HAP/VAP) in the intensive care unit (ICU). The aim of HONEST-PREPS is to set up an infrastructure to prospectively enroll patients at risks of HAP/VAP in the ICU. Collected data will be used to inform future diagnostic, preventative and therapeutic trials. In addition to capturing HAP/VAP episodes in a timely manner.